Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by stockman6767on Jul 03, 2014 12:12pm
425 Views
Post# 22713273

Something I received from Edison

Something I received from Edison

Arrowhead Research - New drug candidate revealedClick for report

Arrowhead announced at its recent analyst day its new RNAi-based drug candidate, ARC-AAT, which is developed for alpha-1 antitrypsin deficiency (AATD). ARC-AAT consists of Arrowhead’s unique DPC delivery vehicle and an RNAi molecule based on a new RNA chemistry, and is able to achieve over 95% knockdown of the target protein in animal models. Arrowhead plans to file an IND of ARC-AAT in Q414, right after the release of its top-line results of the Phase IIa trial of ARC-520 in patients with chronic HBV infection in Q314. Our valuation is $1,075m, equivalent to $20.7/per basic share (or $17.3/per diluted share).

Arrowhead Research is a clinical-stage RNAi company with development programmes in chronic hepatitis B virus (HBV) infection, and rare diseases. Its lead product candidate is ARC-520 (Phase IIa) for HBV based on a proprietary delivery technology called dynamic polyconjugate (DPC). Its second drug candidate, ARC-AAT, will enter clinical trials in Q414.

Bullboard Posts